A Cost-Benefit Assessment of Abuse Deterrent Opioids Wayne Winegarden, Ph.D. Sr. Fellow, Business & Economics, Pacific Research Institute Contributing.

Slides:



Advertisements
Similar presentations
National Institute on Drug Abuse P rescription D rug A buse: An Escalating Public Health Threat P rescription D rug A buse: An Escalating Public Health.
Advertisements

1. Health Policy Research Group Department of Pharmacology & Therapeutics, College of Medicine, University of Nigeria Enugu Campus 2. Department of Clinical.
Innovations: Using a Clinical Pharmacist as a Vehicle for Successful P4P Outcomes Lisa Meland, B.S., PharmD. Helen Pervanas, R.Ph. WellPoint-WellPoint.
Quality improvement for asthma care: The asthma care return-on-investment calculator Ginger Smith Carls, M.A., Thomson Healthcare (Medstat) State Healthcare.
1 1 DSHS | Planning, Performance and Accountability ● Research and Data Analysis Division ● FEBRUARY 2011 Substance Abuse Treatment Opportunities for Health.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence November-December 2007.
The University of North Carolina Healthcare – Current Realities – New Opportunities.
The Impact of Employee Wellness on 4-Year Healthcare Costs May 14, 2009 Brian Day, Ed.D Health Plan Informatics.
Two Goals of Today’s Talk 1.Review some research on the value of increased longevity 2.Link the results of that research to important policy questions.
The Facts About Rising Health Care Costs.
Introduction Health Economics. A course in applied microeconomics, which uses microeconomics to understand the healthcare system or the market for healthcare.
Prescription Drug Abuse Sharon Hertz, M.D. Medical Officer Division of Anesthetic, Critical Care and Addiction Drug Products Food and Drug Administration.
Management of Hepatitis C: An Unprecedented Challenge for Corrections Brad Livingston Executive Director, Texas Department of Criminal Justice Lannette.
Health Care We must address the crushing cost of health care. This is a cost that now causes a bankruptcy in America every thirty seconds. By the end of.
3rd Baltic Conference on Medicines Economic Evaluation, Reimbursement and Rational Use of Pharmaceuticals Pricing and Reimbursement of Pharmaceuticals.
CH 1. Factors accounting for the growth of importance in the health sector  Global health and longevity gains  Expansion of health sector throughout.
Delaware Health and Social Services NAMI Delaware Conference: January 24, 2013 Rita Landgraf, Secretary, Department of Health and Social Services ACA and.
The Business Case for Bidirectional Integrated Care: Mental Health and Substance Use Services in Primary Care Settings and Primary Care Services in Specialty.
Click to jump back to the Trivia machine Helpful trivia for the Do-It-Yourself health planner Increase your knowledge and plan a healthy life with healthy.
Characteristics of Patients Using Extreme Opioid Dosages in the Treatment of Chronic Low Back Pain In this sample of 204 participants, 70% were female,
Scientific Evidence Module 2. The evidence of effectiveness Most research is on methadone, much less on other medications Has proven effective for the.
Opioid Use: What are the technological, clinical, ethical, and regulatory issues? Michael Von Korff Group Health Research Institute.
1 Alcohol and Substance Abuse Council of Jefferson County, Inc. 167 Polk Street, Suite 320 Watertown, New York Voice: ; Fax: ;
Name Institution Date. Description of the Target Population The target population for this study are the African- American population aged between
Mohammad Aljawadi PharmD, PhD Clinical Pharmacy Department King Saud University PHCL 431 Sep, 2015.
Trends and patterns in pharmaceutical use in Australia: What can we learn from those who have gone before us? Nicole Lee Roger Nicholas Ann Roche.
OUTLINE OF HEALTH CARE PLAN RICHARD R. SCHNEIDER, MD F.A.C.P., F.A.C.C.
H.R Prescription drug abuse prevention and treatment Act of 2011.
Obesity, Medication Use and Expenditures among Nonelderly Adults with Asthma Eric M. Sarpong AHRQ Conference September 10, 2012.
Appendices. Appendix 1: Supplementary Data Tables Trends in the Overall Health Care Market.
Prescription Drug Expenditures and Healthcare Burdens in the Medicaid Population G. Edward Miller, Jessica S. Banthin and Thomas M Selden AHRQ Conference.
Improving Value in Health Care: Challenges and Potential Strategies Arnold M Epstein October 24, 2008 Congressional Health Care Reform Education Project.
The National Health Expenditure Accounts Team
TM Making the Case to Insurance Purchasers for Tobacco Use Treatment Coverage Maya Vijayaraghavan, Ph.D. Office on Smoking and Health National Conference.
Growth in prescription spending had slowed, but increased rapidly in 2014 and 2015 Average annual growth rate of prescription drug spending per capita.
1 National Estimates from the Drug Abuse Warning Network Judy K. Ball, Ph.D., M.P.A. Office of Applied Studies Substance Abuse and Mental Health Services.
Abuse-Deterrent Opioids: FDA’s Role and Emerging Challenges Jeanne Ireland Principal, Ireland Strategies, LLC 2015 CWAG Annual Meeting.
Connecticut Pharmaceutical Forum: Access, Affordability, and Better Health Tara C. F. Ryan May 17, 2016.
Testimony of Sidney Wolfe, M.D. Health Research Group of Public Citizen FDA Drug Safety and Risk Management and Anesthetic and Analgesic Drug Products.
Peterson-Kaiser Health System Tracker What are the recent and forecasted trends in prescription drug spending?
Mental Health and Substance Abuse Prescription Drug Spending Trends: Medicaid and Privately Insured Populations American Public Health Association Annual.
Prescription Drug Monitoring Presented by: Len Abbott, Ph.D. Director Science and Technology Kathleen Valentine, General Manager PDM & Toxicology May 14,
Denis G. Patterson, DO ECHO Project April 20, 2016 CDC Guidelines for Prescribing Opioids for Chronic Pain.
Wireless Access SSID: cwag2017
screening, brief intervention and referral to treatment
Wireless Access SSID: cwag2017
*Risk Evaluation and Mitigation Strategy
HEALTH ECONOMICS BASICS
National Health Reform is Essential
Growth in prescription spending had slowed, but increased rapidly in 2014 and 2015
5th Annual Empowering Local Leadership Conference
10th Annual Susan Li Conference
Understanding the Opioid Epidemic
Value of Pharmaceuticals in Managed Care Pharmacy
Opioid Prescribing & Monitoring
Mance E. Buttram, PhD Steven P. Kurtz, PhD
Value of Pharmaceuticals in Managed Care Pharmacy
Value of Pharmaceuticals in Managed Care Pharmacy
Complete a legally valid prescription.
The Opioid Epidemic: Crisis in the Workplace
New Opportunities in Medicare
Population Health.
Growth in prescription spending had slowed, but increased rapidly in 2014 and 2015
Impact of Policy and Regulatory Responses to the Opioid Epidemic on the Care of People with Serious Illness Hemi Tewarson, Director, Health Division National.
Minnesota Health Care Spending and Cost Drivers
Opioid prescribing workflow in the electronic medical record.
Contemporary Clinical Opioid Use: Opportunities and Challenges
Strategic Initiatives to Address Opioid Overdose & Addiction
Medication Assisted Treatment of Opioid Use Disorder
Value of Pharmaceuticals in Managed Care Pharmacy
Presentation transcript:

A Cost-Benefit Assessment of Abuse Deterrent Opioids Wayne Winegarden, Ph.D. Sr. Fellow, Business & Economics, Pacific Research Institute Contributing Editor, EconoSTATS a project of George Mason University Partner, Capitol Economic Advisors Presentation CWAG Annual Conference July 20, 2015

The Findings in Brief Are ADO’s a Cost Effective Means to Lessen the Conflict? Initial studies are finding that abuse-deterrent opioids (ADO) reduce the problem of opioid abuse This study compared the estimated dollar benefit from reduced opioid abuse to an estimate of the higher costs of ADO medications Based on these estimates, there is a net economic benefit from prescribing ADO’s ranging from $1,757 per patient to $4,033 per patient In conflict Opioids are an important treatment option for pain and chronic pain patients Abuse and diversion of opioids imposes health care & societal costs

The Costs of Pain Some level of chronic pain afflicts over 100 million Americans Opioids are an important therapy that helps those suffering the most from chronic pain, and patients with short-term needs (e.g. post surgery) The economic costs from chronic pain include higher healthcare costs and lower productivity at work $’s in billions Estimated Aggregate Cost of Chronic Pain

The Costs of Opioid Abuse More than 16,000 people die every year from overdoses involving pain medication (CDC) 1 in 20 people in the U.S. age 12 and older reported using prescription pain medicines for nonmedical reasons Opioid analgesics were involved in 30% of drug overdose deaths in % in 2010 Opioid-related overdose deaths now outnumber overdose deaths involving all illicit drugs combined.* $’s in billions Total Costs: $55.7 billion Estimated Aggregate Cost of Opioid Abuse * Addressing Prescription Drug Abuse in the United States: Current Activities and Future Opportunities” The Behavioral Health Coordinating Committee Prescription Drug Abuse Subcommittee U.S. Department of Health and Human Services.*

The Potential Role of Abuse-Deterrent Opioids Success Requires Combination of Tools… Physician/patient education Prescription monitoring Serially numbered prescriptions Physician–patient contracts Photo ID requirements Urine drug toxicology screening Safe disposal provisions for unused opioids Clinical questionnaires …Including Abuse-Deterrent Opioids Fortress Approach: Maintain extended-release characteristics despite crushing or dissolving Neutralizing Approach: Tampering with the formulation releases a neutralizing antagonist Aversive Approach: Results in un-pleasant side effects when a large quantity is ingested

Preliminary Findings on the Effectiveness of Abuse-Deterrent Opioids: Excess Healthcare Costs Excess annual per-patient medical costs associated with diagnosed opioid abuse were $9,456 for commercially-insured patients and $11,501 for Medicaid-insured patients “The introduction of reformulated ER oxycodone was associated with relative reductions in rates of diagnosed opioid abuse of 22.7% and 18.0% among commercially- insured and Medicaid patients, respectively.” Rossiter, Louis F., Kirson, Noam Y., Shei, Amie, White, Alan G., Birnbaum, Howard G., Ben-Joseph, Rami, Michna, Edward (2014) “Medical cost savings associated with an extended-release opioid with abuse-deterrent technology in the US” Journal of Medical Economics Vol. 17, No. 4, 2014, 279–287.

Preliminary Findings on the Effectiveness of Abuse-Deterrent Opioids: Total Costs In addition to medical costs, opioid abuse also imposes: Workplace costs Criminal justice costs Accounting for all 3 categories of costs, Kirson et al. (2014) found $1.04 billion in cost reductions due to reformulated ER oxycodone (ADO) Kirson, Noam Y, Shei, Amie, White, Alan G., Birnbaum, Howard G., Ben-Joseph, Rami, Rossiter, Louis F., Michna, Edward (2014) “Societal Economic Benefits Associated with an Extended-Release Opioid with Abuse-Deterrent Technology in the United States” Pain Medicine; 15: 1450–1454. $’s in millions Total Cost Savings: $1.04 billion Estimated Aggregate Cost Reduction Due to Reformulated ER Oxycodone

Total Annual Benefits per Patient from Abuse-deterrent Opioids (2) Additional Per- patient Annual Cost Premium of Abusers (3) Percentage Reduction (4) Benefit per Patient Health expenses commercially-insured$9, %$2, Health expenses Medicaid/Uninsured$11, %$2, Non-health related expenses$12, %$2, Total commercially-insured population $4, Total Medicaid/uninsured population $4, The potential benefits of abuse-deterrent opioids (column 4) is estimated as the reduced costs from lower the number of opioid abusers (measured on a per patient) basis (column 2) To obtain these benefits, the abuse-deterrent opioid needs to be provided to the entire population. Therefore the potential cost savings between $9,456 and $11,501 (column 2) needs to be weighted by the reduction in the rate of diagnosed opioid abuse (column 3). Author calculations based on: (1)Rossiter, Louis F., Kirson, Noam Y., Shei, Amie, White, Alan G., Birnbaum, Howard G., Ben-Joseph, Rami, Michna, Edward (2014) “Medical cost savings associated with an extended-release opioid with abuse-deterrent technology in the US” Journal of Medical Economics Vol. 17, No. 4, 2014, 279–287. (2)Kirson, Noam Y, Shei, Amie, White, Alan G., Birnbaum, Howard G., Ben-Joseph, Rami, Rossiter, Louis F., Michna, Edward (2014) “Societal Economic Benefits Associated with an Extended-Release Opioid with Abuse-Deterrent Technology in the United States” Pain Medicine; 15: 1450– 1454.

Estimating the Current Higher Costs for ADO Drugs Due to ADO’s being patented, generally, gaining the $4,568 to $4,645 in benefits per opioid patient, requires additional market expenditures ADO cost premium based on current opioid prices * Lower-end estimate = the average cost of patented opioids minus average cost of generic opioids Higher-end estimate = the most expensive patented opioid price minus the lowest priced generic price Prices need to be annualized to match annual benefit * Author calculations based on prices from “Treating Chronic Pain with Opioids: Comparing Effectiveness and Cost” According to the report, “Prices are based on nationwide retail average prices for July Consumer Reports Best Buy Drugs obtained prices from data provided by Source Healthcare Analytics, Inc., which is not involved in our analysis or recommendations.”

Estimating the Current Higher Costs for ADO Drugs Calculations based on slightly more than 4 opioid prescriptions per patient prescribed annually Average Price One MonthAnnualized Patented $373 $ Generic $233 Price Gap $144 Largest Gap Patented $692 $2, Generic $48 Price Gap $644 * Author calculations based on prices from “Treating Chronic Pain with Opioids: Comparing Effectiveness and Cost” According to the report, “Prices are based on nationwide retail average prices for July Consumer Reports Best Buy Drugs obtained prices from data provided by Source Healthcare Analytics, Inc., which is not involved in our analysis or recommendations.”

Total Annual Net Benefits per Patient from Abuse-deterrent Opioids The net benefit is simply the additional benefits minus the estimated additional costs Average Price Net Benefit per Opioid Patient Net Benefit Commercially-insured Population$4, Net Benefit Medicaid/uninsured Population$3, Largest Gap Net Benefit per Opioid Patient Net Benefit Commercially-insured Population$1, Net Benefit Medicaid/uninsured Population$1,757.18

Takeaways Promising technology: Based on research of ADOs’ effectiveness, and current price gaps, the overall societal benefit from prescribing ADOs exceeds the additional outlays required Caveats: More research is needed to confirm ADOs impact ADO technology requires other abuse-deterrent tools External benefits: while payers cover the costs, they do not gain all of the benefits (e.g. lower criminal justice costs)